Author: Burcu Kilic

NEW ANALYSIS: NAFTA 2.0 (U.S.-Mexico-Canada Agreement) Pharmaceutical Related Patent Provisions

The revised North American Free trade Agreement (NAFTA 2.0), rebranded by the Trump Administration as the U.S.-Mexico-Canada Agreement or USMCA, was signed last Friday during the G20 summit in Argentina. NAFTA 2.0 is an updated version of the nearly 25-year-old NAFTA, with significant and harmful changes to the intellectual property (IP) provisions, which build on the harmful TRIPS-plus standards in other U.S. free trade agreements since NAFTA 1.0.

Read More

Follow

Facebook     Twitter

PIJIP

infojustice.org is  hosted by the Program on Information Justice and Intellectual Property at American University Washington College of Law.

Infojustice Roundup

Free to Share

RSS Comments on:

  • An error has occurred, which probably means the feed is down. Try again later.

RSS Civil Society Documents

  • An error has occurred, which probably means the feed is down. Try again later.

RSS Comments on:

  • An error has occurred, which probably means the feed is down. Try again later.